Renaissance Capital logo

Immuneering Priced, Nasdaq: IMRX

Preclinical biotech targeting signaling pathways to treat cancer and neurological diseases.

Industry: Health Care

Latest Trade: $26.37 +0.38 (+1.5%)

First Day Return: +17.3%

Return from IPO: +73.3%

Industry: Health Care

We are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. We have more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, we developed a disease-agnostic platform that enables us to utilize human data, novel biology and chemistry, and translational planning to create and advance our wholly owned pipeline. Our current development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and other oncologic signaling pathways. Our lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. We plan to submit an IND for IMM-1-104 to the FDA in the first quarter of 2022. In addition, we anticipate filing at least two additional INDs for our other oncology programs, one in each of 2023 and 2024.
more less
IPO News for Immuneering
more
IPO Data
IPO File Date 07/09/2021
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 7.5
Deal Size ($mm) $113
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/29/2021
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 7.5
Deal Size ($mm) $113
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2008
Employees 32
Website immuneering.com